Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-25-109137
Filing Date
2025-11-10
Accepted
2025-11-10 16:06:53
Documents
70
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q cldx-20250930x10q.htm   iXBRL 10-Q 1485010
2 EX-10.1 cldx-20250930xex10d1.htm EX-10.1 133703
3 EX-31.1 cldx-20250930xex31d1.htm EX-31.1 11522
4 EX-31.2 cldx-20250930xex31d2.htm EX-31.2 11359
5 EX-32.1 cldx-20250930xex32d1.htm EX-32.1 6939
  Complete submission text file 0001104659-25-109137.txt   6958128

Data Files

Seq Description Document Type Size
6 EX-101.SCH cldx-20250930.xsd EX-101.SCH 36062
7 EX-101.CAL cldx-20250930_cal.xml EX-101.CAL 42286
8 EX-101.DEF cldx-20250930_def.xml EX-101.DEF 151569
9 EX-101.LAB cldx-20250930_lab.xml EX-101.LAB 350908
10 EX-101.PRE cldx-20250930_pre.xml EX-101.PRE 251790
73 EXTRACTED XBRL INSTANCE DOCUMENT cldx-20250930x10q_htm.xml XML 1431139
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-15006 | Film No.: 251466185
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)